Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 May 15;118(10):2674-81.
doi: 10.1002/cncr.26553. Epub 2011 Sep 20.

Conditional survival in patients with pancreatic ductal adenocarcinoma resected with curative intent

Affiliations

Conditional survival in patients with pancreatic ductal adenocarcinoma resected with curative intent

Skye C Mayo et al. Cancer. .

Abstract

Background: Prognosis after surgery for pancreatic ductal adenocarcinoma (PDAC) is typically reported from the date of surgery. Survival estimates, however, are dynamic and may change based on the time already survived. The authors sought to assess conditional survival among a large cohort of patients who underwent resection of PDAC.

Methods: Between 1970 and 2008, 1822 patients who underwent resection for PDAC with curative intent were identified. Kaplan-Meier and Cox regression analyses were performed to validate established predictors of survival, and results were compared with 2-year conditional survival.

Results: Actuarial survival was 18% at 5 years, with a median survival of 18 months. Multivariate analysis revealed that tumor size, lymph node ratio, and positive margins were associated with worse survival (all P < .001). Differences in actuarial versus conditional survival estimates were greater the more years already survived by the patient. The 2-year conditional survival at 3 years-the probability of surviving to postoperative year 5 given that the patient had already survived 3 years-was 66% versus a 5-year actuarial survival calculated from the time of surgery of 18%. Stratification of 2-year conditional survival by lymph node ratio and margin status revealed that patients with high lymph node ratio or positive margins saw the greatest increase in 2-year conditional survival as more time elapsed (both P ≤ .01).

Conclusions: Differences in actuarial versus conditional survival estimates were more pronounced based on the additional years already survived by the patient. Conditional survival may be a helpful tool in counseling patients with PDAC, as it is a more accurate assessment of future survival for those patients who have already survived a certain amount of time.

PubMed Disclaimer

Figures

Figure 1
Figure 1
(Top) Overall actuarial survival is stratified by tumor size (P < .01), (Bottom) Two-year conditional survival is stratified by tumor size as a function of time elapsed since surgery (P = 54).
Figure 2
Figure 2
(Top) Overall actuarial survival is stratified by lymph node status (P < .01), (Bottom) Two-year conditional survival is stratified by lymph node status as a function of time elapsed since surgery (P < .001).
Figure 3
Figure 3
(Top) Overall actuarial survival is stratified by surgical margin status (P < .001). (Bottom) Two-year conditional survival is stratified by surgical margin status as a function of time elapsed since surgery (P = .01).
Figure 4
Figure 4
Difference in overall relative survival probabilities compares actuarial versus conditional survival estimates as a function of time elapsed since surgery (eg. time 0 corresponds to the actuarial survival at 2 years). The 2-year conditional survival at 1 year—the probability of surviving to postoperative year 3 given that the patient has already survived 1 year—is 41%. whereas the actuarial survival at 3 years is 27%.

References

    1. Jemal A, Siegel R, Xu J. Ward E. Cancer statistics. CA Cancer J Clin. 2010;2010;60:277–300. - PubMed
    1. Neoptolemos JP, Stocken DD, Friess H, et al. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med. 2004;350:1200–1210. - PubMed
    1. Oettle H, Post S, Neuhaus P, et al. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA. 2007;297:267–277. - PubMed
    1. Ueno H, Kosuge T, Matsuyama Y, et al. A. randomised phase III trial comparing gemcitabine with surgery-only in patients with resected pancreatic cancer: Japanese Study Group of Adjuvant Therapy for Pancreatic Cancer. Br J Cancer. 2009;101:908–915. - PMC - PubMed
    1. Sohn TA, Yeo CJ, Cameron JL, et al. Resected adenocarcinoma of the pancreas—616 patients: results, outcomes, and prognostic indicators. J Gastrointest Surg. 2000;4:567–579. - PubMed